Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Crescita Therapeutics Inc (CTX.TO)

Crescita Therapeutics Inc (CTX.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 13,253
  • Shares Outstanding, K 20,708
  • Annual Sales, $ 22,337 K
  • Annual Income, $ 1,855 K
  • 60-Month Beta 2.11
  • Price/Sales 0.64
  • Price/Cash Flow N/A
  • Price/Book 0.63
  • Price/Earnings ttm 7.11
  • Earnings Per Share ttm 0.09
  • Most Recent Earnings -0.02 on 12/31/19
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.52 +23.08%
on 04/27/20
0.75 -14.67%
on 05/06/20
+0.11 (+20.75%)
since 04/24/20
3-Month
0.40 +60.00%
on 04/17/20
0.99 -35.35%
on 03/03/20
-0.29 (-31.18%)
since 02/25/20
52-Week
0.40 +60.00%
on 04/17/20
1.23 -47.97%
on 07/16/19
-0.25 (-28.09%)
since 05/24/19

Most Recent Stories

More News
Crescita Therapeutics Announces the Results of its Annual General Meeting of Shareholders

, /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research...

CRRTF : 0.5000 (+9.22%)
CTX.TO : 0.64 (+3.23%)
Crescita Therapeutics Announces the Results of its Annual General Meeting of Shareholders

LAVAL, QC , May 14, 2020 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology...

CTX.TO : 0.64 (+3.23%)
CRRTF : 0.5000 (+9.22%)
Crescita Therapeutics Announces Extension of First Quarter 2020 Filings Due to COVID-19

Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) ("Crescita" or the "Company") today announced that pursuant to the exemption provided in Ontario Instrument 51-502 - Temporary Exemption from Certain...

CRRTF : 0.5000 (+9.22%)
CTX.TO : 0.64 (+3.23%)
Crescita Therapeutics Announces Extension of First Quarter 2020 Filings Due to COVID-19

LAVAL, QC , April 28, 2020 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) ("Crescita" or the "Company") today announced that pursuant to the exemption provided in Ontario Instrument...

CTX.TO : 0.64 (+3.23%)
CRRTF : 0.5000 (+9.22%)
Crescita Therapeutics Announces Measures in Response to COVID-19 Virus

Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development ("R&D")...

CRRTF : 0.5000 (+9.22%)
CTX.TO : 0.64 (+3.23%)
Crescita Therapeutics Announces Measures in Response to COVID-19 Virus

LAVAL, QC , March 24, 2020 /PRNewswire/ - Crescita Therapeutics Inc. ( TSX: CTX)  ( OTC US: CRRTF ) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial...

CTX.TO : 0.64 (+3.23%)
CRRTF : 0.5000 (+9.22%)
Crescita Reports Q4 and Fiscal 2019 Results

Record Annual Revenue of $22.3M Record Adjusted EBITDA of $7.0M up from $1.5M

CTX.TO : 0.64 (+3.23%)
CRRTF : 0.5000 (+9.22%)
Pliaglis® finally available in Canada

MONTREAL , March 10, 2020 /CNW Telbec/ - The topical analgesic Pliaglis has long been awaited by many doctors and dermatologists in Canada because it offers patients an effective alternative...

CTX.TO : 0.64 (+3.23%)
Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in Patients with Plaque Psoriasis

Primary Endpoint Achieved with High Statistical Significance

CRRTF : 0.5000 (+9.22%)
CTX.TO : 0.64 (+3.23%)
Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in Patients with Plaque Psoriasis

Primary Endpoint Achieved with High Statistical Significance

CRRTF : 0.5000 (+9.22%)
CTX.TO : 0.64 (+3.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

2nd Resistance Point 0.65
1st Resistance Point 0.64
Last Price 0.64
1st Support Level 0.63
2nd Support Level 0.63

See More

52-Week High 1.23
Fibonacci 61.8% 0.91
Fibonacci 50% 0.81
Fibonacci 38.2% 0.72
Last Price 0.64
52-Week Low 0.40

See More

Business Summary

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar